We are live on ! Find out more
TPTX

Turning Point Therapeutics, Inc. Common Stock
TPTX

Delisted

TPTX was delisted on the 16th of August, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Turning Point Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 208 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 208 → 0 (-208)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $3.06B → $0 (-$3.06B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 208

Holders
–
Holders Change
-208
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
208
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$313M
2
BlackRock
BlackRock
New York
-$285M
3
CAM
Cormorant Asset Management
Massachusetts
-$187M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$144M
5
State Street
State Street
Massachusetts
-$124M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
– -$313M -4,157,552 Closed
BlackRock
2
BlackRock
New York
– -$285M -3,791,801 Closed
CAM
3
Cormorant Asset Management
Massachusetts
– -$187M -2,484,220 Closed
O
4
OrbiMed
New York
– -$151K -2,012,250 Closed
Wellington Management Group
5
Wellington Management Group
Massachusetts
– -$144M -1,910,170 Closed
State Street
6
State Street
Massachusetts
– -$124M -1,650,689 Closed
Fidelity International
7
Fidelity International
Bermuda
– -$87.6M -1,163,475 Closed
FCM
8
Farallon Capital Management
California
– -$87.3M -1,160,000 Closed
AAM
9
Alpine Associates Management
Florida
– -$77.4M -1,028,400 Closed
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
– -$71.8M -953,914 Closed
MF
11
Magnetar Financial
Illinois
– -$69.5K -923,581 Closed
Federated Hermes
12
Federated Hermes
Pennsylvania
– -$69.1M -918,500 Closed
Goldman Sachs
13
Goldman Sachs
New York
– -$68.7M -913,245 Closed
Geode Capital Management
14
Geode Capital Management
Massachusetts
– -$65.6M -871,686 Closed
SFM
15
Soros Fund Management
New York
– -$61.8M -821,635 Closed
UOC
16
UBS O'Connor
Illinois
– -$58.3M -775,000 Closed
Fidelity Investments
17
Fidelity Investments
Massachusetts
– -$53.5M -710,681 Closed
Morgan Stanley
18
Morgan Stanley
New York
– -$50.5M -670,522 Closed
VI
19
Versor Investments
New York
– -$47M -625,067 Closed
Millennium Management
20
Millennium Management
New York
– -$45.9M -610,489 Closed
NAM
21
Nexpoint Asset Management
Texas
– -$45.3M -602,108 Closed
GCL
22
Glazer Capital LLC
New York
– -$45.2M -600,368 Closed
BC
23
Boxer Capital
California
– -$42.9M -570,745 Closed
KL
24
KIM LLC
Kansas
– -$42.6M -566,315 Closed
PCM
25
Pentwater Capital Management
Florida
– -$42.5M -564,714 Closed
1
2 3 4 5

TPTX Hedge Fund Activity: Q3 2022 in Review

0 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q3 2022, worth a combined $0 — down 100% from $3.06B a quarter earlier.

Sellers outnumbered buyers: 208 funds closed out of TPTX and 0 opened new positions — a net loss of 208 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $313M sold.

  • 0 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q3 2022, down from 208 in Q2 2022.
  • Funds reported $0 of Turning Point Therapeutics, Inc. Common Stock stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q3 2022 and 208 closed out, a net change of -208 holders.
  • The largest Turning Point Therapeutics, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $313M sold.

Based on aggregated 13F filings for Q3 2022.